Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Amikacin.
Connection Strength

0.545
  1. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother. 1991 May; 27 Suppl C:15-9.
    View in: PubMed
    Score: 0.117
  2. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987 12 31; 317(27):1692-8.
    View in: PubMed
    Score: 0.093
  3. Review of amikacin usage in the EORTC trials. Am J Med. 1985 Jul 15; 79(1A):17-20.
    View in: PubMed
    Score: 0.079
  4. Synergistic activity of trimethoprim and amikacin against gram-negative bacilli. Antimicrob Agents Chemother. 1977 Sep; 12(3):349-52.
    View in: PubMed
    Score: 0.046
  5. Effect of clindamycin on the in vitro activity of amikacin and gentamicin against gram-negative bacilli. Antimicrob Agents Chemother. 1976 Apr; 9(4):661-4.
    View in: PubMed
    Score: 0.041
  6. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995 Feb; 39(2):445-52.
    View in: PubMed
    Score: 0.038
  7. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May; 35(5):873-8.
    View in: PubMed
    Score: 0.029
  8. In vitro models for the study of combination antibiotic therapy in neutropenic patients. Am J Med. 1986 Jun 30; 80(6B):156-60.
    View in: PubMed
    Score: 0.021
  9. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.021
  10. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986 Feb; 29(2):263-70.
    View in: PubMed
    Score: 0.020
  11. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):463-9.
    View in: PubMed
    Score: 0.015
  12. Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group. J Antimicrob Chemother. 1980 Sep; 6 Suppl A:55-61.
    View in: PubMed
    Score: 0.014
  13. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 1996 May; 40(5):1108-15.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.